Usefulness of denosumab to non squamous non small
-
Upload
rajib-bhattacharjee -
Category
Health & Medicine
-
view
325 -
download
0
Transcript of Usefulness of denosumab to non squamous non small
![Page 1: Usefulness of denosumab to non squamous non small](https://reader031.fdocuments.net/reader031/viewer/2022022414/587a33491a28abdb1c8b5141/html5/thumbnails/1.jpg)
ROLE OF DENOSUMAB IN COMPARISON TO
ZOLEDRONIC ACID IN NSCLC WITH BONE METASTASIS
Presented by
Dr. Rajib BhattacharjeeIPGME&R and SSKM Hospital, Kolkata
![Page 2: Usefulness of denosumab to non squamous non small](https://reader031.fdocuments.net/reader031/viewer/2022022414/587a33491a28abdb1c8b5141/html5/thumbnails/2.jpg)
CANCERS WITH SKELETAL METASTASIS
Predominantly osteolytic•Lung•Thyroid•Kidney•GI Tract•Melanoma
Predominantly osteosclerotic
•Prostate•Medulloblastoma•Carcinoids
Mixed•Breast
![Page 3: Usefulness of denosumab to non squamous non small](https://reader031.fdocuments.net/reader031/viewer/2022022414/587a33491a28abdb1c8b5141/html5/thumbnails/3.jpg)
BACKGROUND Lung cancer is the leading cause of
cancer related deaths worldwide.
Smoking is the main etiological factor.
NSCLC is on the rise especially in never or light smokers. Adenocarcinoma is the common histology in such cases.
30-40% of cases present with skeletal metastasis.
![Page 4: Usefulness of denosumab to non squamous non small](https://reader031.fdocuments.net/reader031/viewer/2022022414/587a33491a28abdb1c8b5141/html5/thumbnails/4.jpg)
APPROACHES TO BONE METASTASIS
Pain killers – NSAIDS, Opioids, Anti-convulsants, Anti-depressants.
Bisphosphonates – Alendronate, Pamidronate, Ibadronate, Zoledronic acid.
Monoclonal antibody – Denosumab
Palliative Irradiation – 8 Gy/1#, 20 Gy/5#, 30Gy/10#
Radiopharmaceuticals – Strontium-89, Samarium-153.
![Page 5: Usefulness of denosumab to non squamous non small](https://reader031.fdocuments.net/reader031/viewer/2022022414/587a33491a28abdb1c8b5141/html5/thumbnails/5.jpg)
ZOLEDRONIC ACID
•Binds to bone minerals and inhibit hydroxyapetite dissolution.
•Inhibits osteoclast maturation.
•Promotes osteoclast apoptosis.
•Inhibits cytoskeletal organisation of osteoclast
•Direct antitumor effect.
•Prevents angiogenesis
![Page 6: Usefulness of denosumab to non squamous non small](https://reader031.fdocuments.net/reader031/viewer/2022022414/587a33491a28abdb1c8b5141/html5/thumbnails/6.jpg)
DENOSUMAB
Binds to RANK-L
Inhibits OCL formation,function and survival
Prevents maturation of OCL
Decreases bone resorption
Breaks the vicious cycle of bone destruction
![Page 7: Usefulness of denosumab to non squamous non small](https://reader031.fdocuments.net/reader031/viewer/2022022414/587a33491a28abdb1c8b5141/html5/thumbnails/7.jpg)
THE TWO AGENTS IN CONTENTION
DENOSUMAB
On November2010, FDA approved
Denosumab for prevention of skeletal related events(SRE) in patients with bone metastasis from solid tumors.
ZOLEDRONIC ACID
In February 2002, FDA approved zoledronic acid (4 mg) for the treatment of multiple myeloma and bone metastases secondary to a wide variety of solid tumors
![Page 8: Usefulness of denosumab to non squamous non small](https://reader031.fdocuments.net/reader031/viewer/2022022414/587a33491a28abdb1c8b5141/html5/thumbnails/8.jpg)
REVIEW OF LITERATURE
DELAYS SRE !
SURVIVAL ADVANTAGE !!
![Page 9: Usefulness of denosumab to non squamous non small](https://reader031.fdocuments.net/reader031/viewer/2022022414/587a33491a28abdb1c8b5141/html5/thumbnails/9.jpg)
STUDY
![Page 10: Usefulness of denosumab to non squamous non small](https://reader031.fdocuments.net/reader031/viewer/2022022414/587a33491a28abdb1c8b5141/html5/thumbnails/10.jpg)
USEFULNESS OF DENOSUMAB TO NONSQUAMOUS NON-SMALL CELL LUNG CANCER PATIENTS WITH BONE METASTASES.
Hibiki Udagawa, Seiji Niho, Keisuke Kirita, Shigeki Umemura, Shingo Matsumoto, Kiyotaka Yoh, Hironobu Ohmatsu, Koichi Goto,
Dept. of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
Journal of Clinical Oncology, 2015 ASCO Annual Meeting.Vol 33, No 15_suppl (May 20 Supplement), 2015: 9609© 2015 American Society of Clinical Oncology
![Page 11: Usefulness of denosumab to non squamous non small](https://reader031.fdocuments.net/reader031/viewer/2022022414/587a33491a28abdb1c8b5141/html5/thumbnails/11.jpg)
METHODS Type of study – Retrospective study
Study duration – May 2010 to April 2014
Selection criteria Age < 75 years Non squamous NSCLC with skeletal metastasis Treated with Platinum doublet or EGFR TKI as 1st line systemic therapy
![Page 12: Usefulness of denosumab to non squamous non small](https://reader031.fdocuments.net/reader031/viewer/2022022414/587a33491a28abdb1c8b5141/html5/thumbnails/12.jpg)
STUDY END POINTS Overall survival (OS)
Progression free survival (PFS)
Time to SRE Pathological fracture Spinal cord compression Radiation or surgery to bone
![Page 13: Usefulness of denosumab to non squamous non small](https://reader031.fdocuments.net/reader031/viewer/2022022414/587a33491a28abdb1c8b5141/html5/thumbnails/13.jpg)
STUDY SCHEMA
Eligible patientsNon squamous NSCLC
with bone mets(n=149)
Dmab group
Denosumab(n=52)
ZA group
Zoledronic acid(n=51)
Non-group
No treatment(n=46)
![Page 14: Usefulness of denosumab to non squamous non small](https://reader031.fdocuments.net/reader031/viewer/2022022414/587a33491a28abdb1c8b5141/html5/thumbnails/14.jpg)
![Page 15: Usefulness of denosumab to non squamous non small](https://reader031.fdocuments.net/reader031/viewer/2022022414/587a33491a28abdb1c8b5141/html5/thumbnails/15.jpg)
PRIOR RATE OF SRE
Series10.00%5.00%
10.00%15.00%20.00%25.00%30.00%35.00%40.00%45.00%50.00%
Dmab
ZA Non
44.2%
43.1%
21.7%
![Page 16: Usefulness of denosumab to non squamous non small](https://reader031.fdocuments.net/reader031/viewer/2022022414/587a33491a28abdb1c8b5141/html5/thumbnails/16.jpg)
PFS IN PATIENTS TREATED WITH PLATINUM BASED CHEMOTHERAPY
Series10
1
2
3
4
5
6
Dmab ZA Non
5.1 mo
3.3 mo
4.3 mo
P = 0.046
![Page 17: Usefulness of denosumab to non squamous non small](https://reader031.fdocuments.net/reader031/viewer/2022022414/587a33491a28abdb1c8b5141/html5/thumbnails/17.jpg)
OVERALL SURVIVAL
Series10
5
10
15
20
25
30
Non
25.4 mo
13.9 mo11.2 mo
Dmab
ZAP = 0.01
![Page 18: Usefulness of denosumab to non squamous non small](https://reader031.fdocuments.net/reader031/viewer/2022022414/587a33491a28abdb1c8b5141/html5/thumbnails/18.jpg)
![Page 19: Usefulness of denosumab to non squamous non small](https://reader031.fdocuments.net/reader031/viewer/2022022414/587a33491a28abdb1c8b5141/html5/thumbnails/19.jpg)
DENOSUMAB MAY IMPROVE OVERALL SURVIVAL COMPARED TO ZOLEDRONIC ACID OR NO TREATMENT IN PATIENTS WITH NON SQUAMOUS NSCLC WITH SKELETAL METASTASIS
![Page 20: Usefulness of denosumab to non squamous non small](https://reader031.fdocuments.net/reader031/viewer/2022022414/587a33491a28abdb1c8b5141/html5/thumbnails/20.jpg)